Guest Editors
Dr. Francois Chevalier
Email: chevalier@ganil.fr
Affiliation: UMR6252 CIMAP, Université de Caen Normandie, Caen, 14000, France
Homepage:
Research Interests: Cancer cellular, biology genomics [q-bio.GN], biochemistry, molecular biology, radiation-biology of radioresistant cancer cells, hypoxic micro-environment and bystander effects in a context of hadrontherapy
Summary
OMICS technologies such as genomics, transcriptomics, proteomics, and metabolomics play a crucial role in cancer biomarker discovery by providing a comprehensive understanding of molecular alterations in tumors. Genomics identifies genetic mutations and variations, while transcriptomics examines gene expression changes. Proteomics explores protein abundance and modifications, and metabolomics analyzes metabolic shifts associated with cancer progression. Integrating these approaches through multi-omics analysis enhances biomarker identification for early detection, prognosis, and personalized treatment strategies. By uncovering novel molecular signatures, OMICS technologies contribute to precision oncology, improving patient outcomes and advancing cancer research.
The purpose of this Special Issue is to deliver recent advances in omics-based applications in cancer helping in biomarker discovery for early diagnosis, prognosis, and appropriate therapeutics.
Keywords
Genomics, transcriptomics, proteomics, metabolomics, biomarkers
Login
Register
Submit a Paper
Propose a Special lssue